| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 3086 | 2017 |
| Treating rheumatoid arthritis to target: recommendations of an international task force JS Smolen, D Aletaha, JWJ Bijlsma, FC Breedveld, D Boumpas, ... Annals of the rheumatic diseases 69 (4), 631-637, 2010 | 2887 | 2010 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs JS Smolen, R Landewé, FC Breedveld, M Dougados, P Emery, ... Annals of the rheumatic diseases 69 (6), 964-975, 2010 | 2378 | 2010 |
| American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials DT Felson, JS Smolen, G Wells, B Zhang, LHD Van Tuyl, J Funovits, ... Arthritis & Rheumatism 63 (3), 573-586, 2011 | 1858 | 2011 |
| Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force JS Smolen, FC Breedveld, GR Burmester, V Bykerk, M Dougados, ... Annals of the rheumatic diseases 75 (1), 3-15, 2016 | 1637 | 2016 |
| Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active‐surveillance report JJ Gómez‐Reino, L Carmona, VR Valverde, EM Mola, MD Montero Arthritis & Rheumatism: Official Journal of the American College of …, 2003 | 1313 | 2003 |
| Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: the … MC Genovese, JD McKay, EL Nasonov, EF Mysler, NA da Silva, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 1123 | 2008 |
| Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis W Hueber, DD Patel, T Dryja, AM Wright, I Koroleva, G Bruin, C Antoni, ... Science translational medicine 2 (52), 52ra72-52ra72, 2010 | 1074 | 2010 |
| Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study G Jones, A Sebba, J Gu, MB Lowenstein, A Calvo, JJ Gomez-Reino, ... Annals of the rheumatic diseases 69 (01), 88-96, 2010 | 1059 | 2010 |
| EULAR recommendations for the management of Behçet disease G Hatemi, A Silman, D Bang, B Bodaghi, AM Chamberlain, A Gul, ... Annals of the rheumatic diseases 67 (12), 1656-1662, 2008 | 994 | 2008 |
| Adipokines as emerging mediators of immune response and inflammation F Lago, C Dieguez, J Gómez-Reino, O Gualillo Nature clinical practice Rheumatology 3 (12), 716-724, 2007 | 814 | 2007 |
| Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists L Carmona, JJ Gómez‐Reino, V Rodríguez‐Valverde, D Montero, ... Arthritis & Rheumatism 52 (6), 1766-1772, 2005 | 813 | 2005 |
| Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty‐four–week efficacy and safety … A Kavanaugh, I McInnes, P Mease, GG Krueger, D Gladman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2009 | 798 | 2009 |
| Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis M Otero, R Lago, R Gomez, F Lago, C Dieguez, JJ Gomez-Reino, ... Annals of the rheumatic diseases 65 (9), 1198-1201, 2006 | 702 | 2006 |
| The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement I Solovic, M Sester, JJ Gomez-Reino, HL Rieder, S Ehlers, HJ Milburn, ... European Respiratory Journal 36 (5), 1185-1206, 2010 | 591 | 2010 |
| Leptin, from fat to inflammation: old questions and new insights M Otero, R Lago, F Lago, FF Casanueva, C Dieguez, JJ Gómez-Reino, ... FEBS letters 579 (2), 295-301, 2005 | 585 | 2005 |
| The emerging role of adipokines as mediators of inflammation and immune responses F Lago, C Dieguez, J Gómez-Reino, O Gualillo Cytokine & growth factor reviews 18 (3-4), 313-325, 2007 | 547 | 2007 |
| Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor A Kavanaugh, PJ Mease, JJ Gomez-Reino, AO Adebajo, J Wollenhaupt, ... Annals of the rheumatic diseases 73 (6), 1020-1026, 2014 | 542 | 2014 |
| Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection JJ Gómez‐Reino, L Carmona, M Ángel Descalzo Arthritis Care & Research: Official Journal of the American College of …, 2007 | 526 | 2007 |
| Leptin in the interplay of inflammation, metabolism and immune system disorders V Abella, M Scotece, J Conde, J Pino, MA Gonzalez-Gay, ... Nature Reviews Rheumatology 13 (2), 100-109, 2017 | 493 | 2017 |
